Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-46 (canceled)

47 (currently amended) A method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque within a mammal, the method comprising increasing the expression or activity of an ER resident calcium-binding protein in said cell by introducing a polynucleotide operably linked to a promoter into said cell, wherein said polynucleotide encodes said ER resident calcium-binding protein, and wherein said ER resident calcium-binding protein is a member selected from the group consisting of GRP78/BiP, GRP94, GRP72, Calreticulin, Calnexin, Reticulocalbin, Protein disulfide isomerase, cis/trans-Prolyl isomerase, and HSP47.

48 (previously presented) The method of claim 47, wherein said cell is an endothelial cell.

49 (previously presented): The method of claim 47, wherein said cell is a smooth muscle cell.

50 (previously presented): The method of claim 47, wherein said cell is a macrophage.

51 (previously presented): The method of claim 47, wherein said cell is a monocyte.

52 (previously presented): The method of claim 47, wherein said ER resident calcium-binding protein is GRP78/BiP.

53 (previously presented): The method of claim 47, wherein said ER resident calcium-binding protein is selected from the group consisting of GRP94, GRP72, Calreticulin, Calnexin, Reticulocalbin, Protein disulfide isomerase, cis/trans-Prolyl isomerase, and HSP47.

54 (previously presented): The method of claim 47, wherein the increase in the expression or activity of said ER resident calcium-binding protein within said cell results in a decrease in the level of tissue factor procoagulant activity on the surface of said cell.

55 (canceled)

56 (previously presented): The method of claim 47, wherein said polynucleotide is introduced into said cell using a viral vector.

57 (previously presented): The method of claim 56, wherein said viral vector is an adenoviral vector.

58 (previously presented): The method of claim 47, wherein said polynucleotide is introduced into said cell using a nonviral vector.

59 (previously presented): The method of claim 58, wherein said nonviral vector is introduced into said cell as naked DNA or using liposome-mediated transfection.

60-61 (canceled)

62 (currently amended): A method of inhibiting the generation of active thrombin on the surface of a cell within a mammal, the method comprising increasing the expression or activity of an ER resident calcium-binding protein in said cell by administering a pro-inflammatory cytokine to said cell, <u>wherein said pro-inflammatory cytokine is a member selected from the group consisting of interleukin-3 and CSF-1</u>.

63-66 (canceled)

67 (previously presented): The method of claim 62, wherein said proinflammatory cytokine is interleukin-3.